Why Merck Might Have A Fight On Its Hands With Its $6.7 Billion Takeover Of Terns

Merck Might Have A Fight On Its Hands With Its $6.7 Billion Takeover Of Terns | Investor's Business Daily IPO TRENDS: SpaceX Is Just One Unicorn To Watch Merck (MRK) made plans Wednesday to beef up its cancer treatment portfolio with the $6.7 billion acquisition of Terns Pharmaceuticals (TERN). But the takeover could be at risk. The price tag is low considering the startlingly good data Terns put out for its chronic myeloid leukemia treatment, TERN-701, William Blair analyst Andy Hsieh said. The deal values ...